News

January 14, 2019January 14, 2019

Coffin-Siris Syndrome Should be Included in the Differential Diagnosis of Angelman Syndrome, Case Study Says

News

Coffin-Siris syndrome (CSS) should be included in the differential diagnosis of Angelman syndrome, say researchers, after describing the case of a 14-year-old boy who harbored a genetic mutation associated ... Read more

January 7, 2019January 7, 2019

Brain Electrical Activity Can Help Evaluate Learning Skills in Nonverbal Angelman Patients

News

Nonverbal Angelman syndrome patients can learn new information by exposure to repeated auditory stimuli, a new study shows. Measuring brain electrical activity can help evaluate patients’ auditory learning and ... Read more

December 21, 2018December 21, 2018

Angelman Syndrome Foundation’s Clinic Network Goes International

News

With the addition of clinics in Canada and Israel, the Angelman Syndrome Foundation (ASF) now has an international network of Angelman Syndrome Clinics staffed with Angelman syndrome (AS) experts. ... Read more

December 21, 2018December 20, 2018

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

News

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to ... Read more

December 14, 2018December 14, 2018

Mothers of Children with Rare Genetic Syndromes Experience Stress Similar to Moms of Autistic Kids, Study Finds

News

A significant proportion of mothers of children with rare genetic syndromes, such as Angelman syndrome, experience levels of stress similar to those reported by mothers of children with autism ... Read more

December 10, 2018December 10, 2018

Ovid Therapeutics to Start Phase 3 Trial of OV101 in Children with Angelman Syndrome

News

Ovid Therapeutics is planning to start a pivotal Phase 3 trial of OV101 (gaboxadol), its investigational oral therapy, in children ages 4-12 with Angelman syndrome. The company’s decision is based ... Read more

December 7, 2018December 7, 2018

Newer Anti-epileptic Therapies May Be Safer, More Effective in Reducing Seizures in Angelman’s Patients

News

Newer anti-epileptic medications — such as Keppra (levetiracetam), Lamitcal (lamotrigine), and clobazam — as well as low glycemic index treatment may be more effective in reducing epileptic seizures and ... Read more

November 30, 2018November 30, 2018

‘World’s Largest’ Newborn Screening Study Includes Angelman Syndrome

News

If successful, an extensive pilot screening study afoot in Australia for Angelman syndrome and three other rare genetic disorders could lead to large-scale testing. With a contribution from the ... Read more

November 16, 2018November 16, 2018

Short-term use of NSI-189 Aids Cognitive and Motor Skills in Angelman Mouse Model, Study Says

News

Short-term treatment with Neuralstem‘s NSI-189 reversed cognitive and motor impairments in a mouse model of Angelman syndrome, according to study results. This early finding could help to pave the way for this compound, in ... Read more

November 9, 2018November 9, 2018

UBE3A Gene Reactivation in Inhibitory Neurons May Prevent Seizures, Angelman Mouse Study Shows

News

Epileptic seizures caused by disturbances in the activity of a specific type of nerve cell called an inhibitory neuron were prevented by the reactivation of the UBE3A gene in young mice with Angelman ... Read more

Pin It on Pinterest